| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

9-12 July 2021

31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2021)

24-25 June 2021

Spring European Virtual MidCap Event

23 June 2021

NewYorkBIO and NYSE’s Emerging Biotech Company Showcase

21 June 2021

ORYZON to present new clinical data and corporate updates at international conferences in June and July

15 June 2021

ORYZON announces FDA approval of IND for PORTICO, a Phase IIb trial with vafidemstat in Borderline Personality Disorder

11 June 2021

ORYZON presents iadademstat ALICE 30-month data at EHA-2021, confirming positive and robust efficacy in combination with azacitidine in AML

28 June 2021

Annual General Shareholders Meeting 2021

14-18 June 2021

BIO International Convention 2021

10-13 June 2021

European Hematology Association (EHA) 2021 Congress

8-9 June 2021

Precision in Drug Discovery & Preclinical Virtual Summit

Pagination

First page «
Previous page ‹
Page 23
Page 24
Page 25
Page 26
Current page 27
Page 28
Page 29
Page 30
Page 31
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel